[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 21, Issue 1 (1-2023) ::
Int J Radiat Res 2023, 21(1): 37-44 Back to browse issues page
Radiotherapy related prognostic factors in brain metastasis patients who have undergone whole brain radiotherapy or with local boost and survived more than 6 months
H.S. Kızıltan, G. Coban, P. Altınok, E. Tekce, A. Mayadagli
Health Sciences University, Basaksehir Cam and Sakura City Hospital, Department of Radiation Oncology, Turkeye , hskiziltan@gmail.com
Abstract:   (65 Views)
Background: In this study, prognostic features of radiation were investigated in cancer patients with 1-10 brain metastases (BM) who have not under surgery and survived longer than 6 months. Materials and Methods: This retrospective study included 136 patients have lung, breast, colon cancer and malign melanoma (MM) with 1-10 BM. All patients and data of BM patients who lived longer than 6 months radiotherapy (RT) related factors affecting their survival rates were examined. Patients were given only WBRT (Whole brain Radiotherapy) in 8-20 fractions with a 160-300 cGy / day fraction, or WBRT with local boost RT with an additional daily 300-350 cGy fraction. Results: When the results were evaluated analysis showed that the having CT, breast cancer, a KPS of 60% or more, daily fraction dose of RT affected survival significantly in all patients. Then subgroub analysis were obtained according to survival rates, number of metastases more than 5 affects life negatively (r=-0.435 and p=0.03) for survival longer than 6 months (SL6m) and survival shorter or equal than 6 months SS6m. The WBRT doses of 3000 cGy with 300 cGy daily fraction size negatively affected life compared to 2500 cGy with 250 cGy  (r=-0.280 and p=0.01). Conclusion: It was determined that KPS > 60 and limiting WBRT doses up to 250 / 2500 cGy daily and total in patients with BM between 1-10 was the important best prognostic factor due to RT for SL6m, which increased patient performance and survival rates.
Keywords: SRS, SBRT, Simultaneous Integrated Boost, brain metastasis, TomoTherapy, radiotherapy.
Full-Text [PDF 684 kb]   (43 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kızıltan H, Coban G, Altınok P, Tekce E, Mayadagli A. Radiotherapy related prognostic factors in brain metastasis patients who have undergone whole brain radiotherapy or with local boost and survived more than 6 months. Int J Radiat Res 2023; 21 (1) :37-44
URL: http://ijrr.com/article-1-4567-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 1 (1-2023) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.07 seconds with 32 queries by YEKTAWEB 4540